Main Article Content
better health, higher drug costs
Dear Editor: The authors Mintzes and Lexchin in their commentary to our paper titled The Value of Medicines in Canada, have cultivated a theme to which we both agree – the need for efficient use of drug therapy. It is our original position that innovative pharmaceuticals, when used appropriately as part of overall disease management, offer value-for-money by increasing both the global quality and quantity of life.
2. Han D, Wang ECY. The Value of Medicines in Canada. Can J Clin Pharmacol 2005;12 (1):e10- e21.
3. Canadian Institute for Health Information. National health expenditure trends, 1975-2002. Ottawa, ON: CIHI, 2002.
4. Policy Research Division, Strategic Policy Directorate, Population an d Public Health Branch, Health Canada. Economic burden of illness in Canada, 1998.2002.
5. Guide to Community Preventive Services. http://www.thecommunityguide.org Accessed December 15, 2003.
6. Canadian Task Force on Preventive Health Care. http://www.ctfphc.org . Accessed January, 2005.
7. Patented Medicines Pricing Review Board. Annual Report 2003. Available at Can J Clin Ph armaco l V ol 12 (1) Winter 2005 :e15 0-e151 ; Mar .200 5 e151 http://pmprb.com/english/View.asp?x=302&mp=91 Accessed January, 200 5
8. Calfee, JE. Prices, Markets, and the Pharmaceutical Revolution. Washington DC: American Enterprise Institute Press, 2000.
9. DiMasi J, Paqu ette C. Th e Economics o f Follow- on Drug Research and Development Trends in Entry Rates and the Timing of Development . Pharmacoeconomics 2 004;22( Supp l.2 ):1-1 4.
10. DiMasi JA, Hans en RW, Grabows ki H G. The price of innovation: new estimates o f d rug development cost s. Journal of Health Economics 2003;22(2): 151-185